AMGN's consistent top-line growth, an interesting pipeline and rising estimates are good enough reasons to stay invested in the stock for now.

Investing.com -- Fitch Ratings has revised its outlook for biopharmaceutical company Amgen Inc (NASDAQ: AMGN ). to positive ...

Rare disease drugs like Tepezza, Krystexxa and Uplizna, added from last year’s acquisition of Horizon Therapeutics, are also boosting top-line growth. Amgen is also evaluating Kyprolis ...

Amgen’s innovative R&D pipeline is promising, with recent approvals for IMDELLTRA™ and BLINCYTO®, and positive clinical data for TEZSPIRE® and UPLIZNA®. The pipeline features potentially ...

Immunovant will use results from its Phase III myasthenia gravis study to support pipeline candidate IMVT-1402 over the trial ...

Zenas BioPharma (ZBIO) stock rises as Wedbush issues a bullish recommendation based on the company's lead asset obexelimab. Read more here.

Amgen is planning to push its olpasiran candidate for reducing lipoprotein(a) into phase 3 as quickly as possible as it tries to catch up with rival programmes at Novartis. The US biotech has just ...

Findings from MINT will be presented at the American Academy of Neurology Annual Meeting on April 8, 2025, in San Diego.